UY38602A - Compuestos tricíclicos condensados - Google Patents

Compuestos tricíclicos condensados

Info

Publication number
UY38602A
UY38602A UY0001038602A UY38602A UY38602A UY 38602 A UY38602 A UY 38602A UY 0001038602 A UY0001038602 A UY 0001038602A UY 38602 A UY38602 A UY 38602A UY 38602 A UY38602 A UY 38602A
Authority
UY
Uruguay
Prior art keywords
tricyclic compounds
condensed tricyclic
refers
compounds
condensed
Prior art date
Application number
UY0001038602A
Other languages
English (en)
Inventor
Gordon Pike Kurt
Grant Kettle Jason
Joseph CASSAR Doyle
Iain Simpson
Christopher Phillips
Scott Boyd
Ross Steward Oliver
Steven Bodnarchuk Michael
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY38602A publication Critical patent/UY38602A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

La memoria descriptiva se refiere a compuestos de Fórmula (A) (A) 5 y sales farmacéuticamente aceptables de los mismos. La memoria descriptiva también se refiere a procesos e intermedios utilizados para su preparación, a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de trastornos proliferativos celulares.
UY0001038602A 2019-03-05 2020-03-05 Compuestos tricíclicos condensados UY38602A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962813885P 2019-03-05 2019-03-05
US201962951146P 2019-12-20 2019-12-20

Publications (1)

Publication Number Publication Date
UY38602A true UY38602A (es) 2020-09-30

Family

ID=69740367

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038602A UY38602A (es) 2019-03-05 2020-03-05 Compuestos tricíclicos condensados

Country Status (23)

Country Link
US (1) US20220204527A1 (es)
EP (1) EP3935060B1 (es)
JP (1) JP7453989B2 (es)
KR (1) KR20210135539A (es)
CN (1) CN113508118A (es)
AU (1) AU2020231045B2 (es)
BR (1) BR112021017408A2 (es)
CA (1) CA3131156A1 (es)
CL (1) CL2021002296A1 (es)
CO (1) CO2021012381A2 (es)
CR (1) CR20210504A (es)
DO (1) DOP2021000183A (es)
EC (1) ECSP21073246A (es)
IL (1) IL285761A (es)
JO (1) JOP20210241A1 (es)
MA (1) MA55198A (es)
MX (1) MX2021010674A (es)
PE (1) PE20220140A1 (es)
SG (1) SG11202109451TA (es)
TW (1) TW202100532A (es)
UY (1) UY38602A (es)
WO (1) WO2020178282A1 (es)
ZA (1) ZA202106192B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
JP2022517222A (ja) 2019-01-10 2022-03-07 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
BR112022003543A2 (pt) 2019-08-29 2022-05-24 Array Biopharma Inc Inibidores de kras g12
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
EP4051678A1 (en) 2019-10-28 2022-09-07 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
PL3886991T3 (pl) * 2019-12-11 2022-11-21 Eli Lilly And Company Inhibitory KRAS G12C
AU2020405170A1 (en) 2019-12-20 2022-06-30 Mirati Therapeutics, Inc. SOS1 inhibitors
TWI799871B (zh) * 2020-05-27 2023-04-21 大陸商勁方醫藥科技(上海)有限公司 三環并環類化合物，其製法與醫藥上的用途
MX2022016355A (es) 2020-06-18 2023-04-03 Revolution Medicines Inc Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
IL301062A (en) 2020-09-03 2023-05-01 Revolution Medicines Inc Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
CN114539286B (zh) * 2020-11-24 2024-02-02 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用
TW202235082A (zh) 2020-12-04 2022-09-16 美商美國禮來大藥廠 Ｋｒａｓ ｇ１２ｃ抑制劑
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
TW202304934A (zh) * 2021-04-08 2023-02-01 美商建南德克公司 非環氧氮呯化合物及其用途
KR20240055778A (ko) 2021-09-01 2024-04-29 노파르티스 아게 Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도
WO2023072297A1 (zh) * 2021-11-01 2023-05-04 江苏恒瑞医药股份有限公司 含氮的四环化合物、其制备方法及其在医药上的应用
TW202333800A (zh) 2021-12-28 2023-09-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及rasg12c抑制劑之組合
WO2023168036A1 (en) 2022-03-04 2023-09-07 Eli Lilly And Company Method of treatment including kras g12c inhibitors and shp2 inhibitors
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318412A1 (en) * 2006-07-11 2009-12-24 Takahiro Matsumoto Tricyclic heterocyclic compound and use thereof
NO2714752T3 (es) * 2014-05-08 2018-04-21
GB201409624D0 (en) * 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CA3061650A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物

Also Published As

Publication number Publication date
JP7453989B2 (ja) 2024-03-21
WO2020178282A1 (en) 2020-09-10
AU2020231045B2 (en) 2023-03-16
ZA202106192B (en) 2022-08-31
US20220204527A1 (en) 2022-06-30
MX2021010674A (es) 2021-09-28
EP3935060C0 (en) 2023-11-15
CL2021002296A1 (es) 2022-04-29
KR20210135539A (ko) 2021-11-15
PE20220140A1 (es) 2022-01-27
SG11202109451TA (en) 2021-09-29
JP2022523981A (ja) 2022-04-27
EP3935060B1 (en) 2023-11-15
MA55198A (fr) 2022-01-12
CN113508118A (zh) 2021-10-15
CR20210504A (es) 2022-02-08
JOP20210241A1 (ar) 2023-01-30
IL285761A (en) 2021-10-31
CA3131156A1 (en) 2020-09-10
CO2021012381A2 (es) 2021-10-20
EP3935060A1 (en) 2022-01-12
ECSP21073246A (es) 2021-11-30
DOP2021000183A (es) 2021-09-30
AU2020231045A1 (en) 2021-10-28
TW202100532A (zh) 2021-01-01
BR112021017408A2 (pt) 2022-01-18

Similar Documents

Publication Publication Date Title
UY38602A (es) Compuestos tricíclicos condensados
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
NI201900039A (es) Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer
CL2021000191A1 (es) Inhibidores de inflamasoma nlrp3
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
CO2019008941A2 (es) Moduladores del receptor de estrógeno
CL2022000201A1 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
UY35275A (es) Derivados de aminopirazina
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CO2024002844A2 (es) Compuestos espirocíclicos
ECSP22049160A (es) Derivados de bencimidazol
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
CO2021001925A2 (es) Piridopirimidinas como inhibidores del receptor de histamina h4
EA202192366A1 (ru) Конденсированные трициклические соединения, применимые в качестве противораковых средств